One of the biggest financing rounds for furthering the work of a young researcher has just been completed at EPFL. The microscopic electrodes developed by André Mercanzini - which are currently in clinical trials - could revolutionize Deep Brain Stimulation. The microelectrodes developed by André Mercanzini should generate a lot of interest from investors: they have the potential to reduce side-effects, the risk of complications, and cost. At a time when Deep Brain Stimulation (DBS) has an increasing number of applications - such as the treatment of pain relief, epilepsy and depression - the market for these products is estimated to be around 450 million Swiss francs. "It should grow at about 25% each year," notes Jean-Pierre Rosat, CEO of Aleva Neurotherapeutics. The start-up, launched by the young scientist in 2008, has just completed a round of financing that raised 10 million francs, thanks to BiomedInvest AG, BB Biotech Ventures III, Initiative Capital Romandie, and private investors. It's almost certainly a record for the school for an innovative product resulting from doctoral work over the last ten years.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
Your Benefits
- Access to all content
- Receive newsmails for news and jobs
- Post ads
